Inventiva shares surge 11.80% intraday as Leerink initiates coverage with Outperform rating and $12 price target.

Inventiva surged 11.80% intraday after Leerink Partners initiated coverage with an "Outperform" rating and a $12 price target, signaling strong analyst confidence. The firm highlighted the company’s NATiV3 Phase 3 trial for lanifibranor, a NASH treatment, and its $172.5 million equity financing to advance the program. This follows recent positive ratings from UBS, Guggenheim, and others, reinforcing optimism about Inventiva’s clinical-stage pipeline and partnerships with AbbVie and BI. The move aligns with the stock’s 122.58% annual performance, driven by its focus on unmet medical needs in NASH and rare diseases.